This was the stock's second consecutive day of gains.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

This summary highlights pressing health-related issues worldwide. Topics include President Trump considering protective ...

Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024Gianluca Fuggetta Will Assume The Role Of Senior Vice President, ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...

This is the second volume of the Research Topic titled 'Novel Insights into CAR T-cell Associated Neurotoxicity'. You may ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...